What is claimed is:

1. A liposomal system comprising:

(a) a peptide having a ubiquitinatable region and an antigenic region,

(b) a pH-sensitive liposomal carrier; and

(c) a bilayer-associated adjuvant.

2. The liposomal system of claim 1, wherein the ubiquitinatable region comprises Seq. ID No. 2

3. The liposomal system of claim 2, wherein the antigenic region is an oncofusion protein breakpoint region.

4. The liposomal system of claim 3, wherein the antigenic region comprises a leukemia-associated oncofusion protein breakpoint region selected from the group consisting of E2A/PBX1, PML/RAR and BCR/abl.

5. The liposomal system of claim 3, wherein the antigenic region comprises a sarcoma-associated oncofusion protein breakpoint region selected from the group consisting of PAX3/FKHR, EWS/FLI1, TLS/CHOP and SYT/SSX, and ASPL/TFE3 .

6. The liposomal system of claim 3, wherein the antigenic region comprises a EWS/ATF1 melanoma of soft parts-associated oncofusion protein breakpoint region.

7. The liposomal system of claim 1, wherein the antigenic region is an oncofusion protein breakpoint region.

8. The liposomal system of claim 7, wherein the antigenic region comprises a leukemia-associated oncofusion protein breakpoint region selected from the group consisting of E2A/PBX1, PML/RAR and BCR/abl.

9. The liposomal system of claim 7, wherein the antigenic region comprises a sarcoma-associated oncofusion protein breakpoint region selected from the group consisting of PAX3/FKHR,EWS/FLI1, TLS/CHOP , SYT/SSX, and ASPL/TFE3 .

10. The liposomal system of claim 7, wherein the antigenic region comprises a EWS/ATF1 melanoma of soft parts-associated oncofusion protein breakpoint region.

11. The liposomal system of claim 1, wherein the antigenic region comprises a protein or peptide sequence containing a MHC-I-restricted epitope or MHC-I-restricted heteroclitic epitope.

12. The liposomal system of claim 11, wherein the ubiquitinatable region comprises Seq. ID No. 2

13. The liposomal system of claim 1, wherein the bilayer-associated adjuvant is monophosphoryl Lipid A.

14. The liposomal system of claim 1, wherein the bilayer-associated adjuvant is CPG-cholesterol.

15. The liposomal system of claim 14, wherein the CPG-cholesterol comprises Seq. ID No. 4.

16. A method for treating a cancer in a patient, wherein the cancer has a specific antigen associated with it, comprising the step administer to the patient a therapeutically effective amount of a liposome comprising
(a) a peptide having a ubiquitinatable region and an antigenic region,
(b) a pH-sensitive liposomal carrier; and
(c) a bilayer-associated adjuvant,
wherein the antigenic region of the peptide comprises an epitope of the specific antigen associated with the cancer.

17. The method of claim 16, wherein the ubiquitinatable region comprises Seq. ID No. 2

18. The method of claim 17, wherein the antigenic region is an oncofusion protein breakpoint region.

19. The method of claim 18, wherein the cancer is a leukemia, and the antigenic region comprises a leukemia-associated oncofusion protein breakpoint region selected from the group consisting of E2A/PBX1, PML/RAR and BCR/abl.

20. The method of claim 18, wherein the cancer is a sarcoma and the antigenic region comprises a sarcoma-associated oncofusion protein breakpoint region selected from the group consisting of PAX3/FKHR, EWS/FLI1, TLS/CHOP, SYT/SSX, and ASPL/TFE3 .

21. The method of claim 18, wherein the cancer is melanoma and the antigenic region comprises a EWS/ATF1 melanoma of soft parts-associated oncofusion protein breakpoint region.

22. The method of claim 16, wherein the antigenic region is an oncofusion protein breakpoint region.

23. The method of claim 22, wherein the cancer is a leukemia, and the antigenic region comprises a leukemia-associated oncofusion protein breakpoint region selected from the group consisting of E2A/PBX1, PML/RAR and BCR/abl.

23. The method of claim 22, wherein the cancer is a sarcoma and the antigenic region comprises a sarcoma-associated oncofusion protein breakpoint region selected from the group consisting of PAX3/FKHR, EWS/FLI1, TLS/CHOP , SYT/SSX and ASPL/TFE3 .

24. The method of claim 22, wherein the cancer is melanoma and the antigenic region comprises a EWS/ATF1 melanoma-associated oncofusion protein breakpoint region.

25. The method of claim 16, wherein the antigenic region comprises a protein or peptide sequence containing a MHC-I-restricted epitope or MHC-I-restricted heteroclitic epitope.

26. The method of claim 25, wherein the ubiquitinatable region comprises Seq. ID No. 2

27. The method of claim 16, wherein the bilayer-associated adjuvant is monophosphoryl Lipid A.

28. The method of claim 16, wherein the bilayer-associated adjuvant is CPG-cholesterol.

29. The method of claim 28, wherein the CPG-cholesterol comprises Seq. ID No. 4.